Immatics Announces Third Quarter 2026 Financial Results and Business Update
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤SUPRAME randomizations on track to complete by year-end; topline PFS data expected H1 2027
- ➤Cash and financial assets $536.3 million; cash runway projected through Q4 2028
- ➤IMA203CD8 gynecologic cancers delivered 55% cORR and 8.4-month mDOR
- ➤IMA402 PRAME-high melanoma achieved 32% cORR, 12.5-month mDOR, 91% one-year OS
- ➤Q3 revenue $7.8 million, up from $5.9 million; net loss widened to $86.3 million
Expert Statements
Harpreet Singh, Chief Executive Officer and Co-Founder of Immatics
“Our focus is clear: completing enrollment in the Phase 3 SUPRAME trial and preparing for the BLA filing for anzu-cel in melanoma. In addition, we continue to advance our Phase 1/2 bispecific and cell therapy programs across multiple cancer types.”
Harpreet Singh, Chief Executive Officer and Co-Founder of Immatics
“Everything we do is guided by patients with cancer who urgently need new treatment options. This commitment drives our continued work across the PRAME franchise and our preparations for the anticipated launch of anzu-cel, positioning us well as we enter what we expect to be the defining year for Immatics.”
* Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint
* SUPRAME topline data disclosure remains expected in H1 2027, followed by BLA submission in 2027
Get started
Create a free account to read the full story.